High rates of ARID1A mutations were observed in 46–57% of ovarian clear cell carcinomas, 30% of ovarian endometrioid carcinomas and 40% of uterine endometrioid carcinomas [15,47,48]. Here, ARID1A is linked to ovarian clear cell cancer.